Influenza vaccine: FluGen demonstrates vaccine-induced protection against a highly drifted H3N2 influenza virus in a human challenge study

NewsDesk @bactiman63 Clinical-stage vaccine company, FluGen today announced the publication of results from its Phase 2 human challenge study of Bris2007 M2SR, the Company's investigational, supra-seasonal, live, single-replication, intranasal influenza (flu) vaccine. Results published in the Journal of Infectious Diseases show that subjects with vaccine-induced neutralizing antibodies were protected against infection and illness following challenge with an antigenically [...]

The post Influenza vaccine: FluGen demonstrates vaccine-induced protection against a highly drifted H3N2 influenza virus in a human challenge study appeared first on Outbreak News Today.